Research and Markets: View this Complete and Systematic Description of Past, Present and Future Efforts in Breast Cancer R&D.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c23164) has announced the addition of Basic Platform Report: Breast Cancer to their offering. "Basic Platform Report: Breast Cancer " provides a complete and systematic description of the past present and future efforts in cancer R&D, focused on the breast cancer field. Structured and defined information necessary to analyze the breast cancer drug candidates currently under development has been identified. More than 150 industry related R&D strategies have been identified. Several thousands of records from a multitude of sources build the structure and content of this report. The report is divided in 6 sections each section structured to enable the study of a specific topic: Section I: Investigators Section II: Drug candidates Section III: Developmental stage Section IV: Therapeutic types Section V: Mechanism of action & targets Section VI: Drug effects "Basic Platform Report: Breast Cancer " is a unique gathering of information found no were else. The information structure will provide an easy reading format to track B2B (Business to Business) Refers to one business communicating with or selling to another. See B2B e-commerce, B2C and B2G. B2B - business to business collaborations and industry academic relationships as well as identify candidates receiving Fast Track Designations and Orphan Drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the Status. Example of candidates included: The complete number of candidate drugs in clinical research for breast cancer, are more than 150 and some of them are listed below: Abraxane, Alimta, Arimidex, Aromasin, Avastin, BMS-217380-01, BMS-247550, CAELYX, CCI-779, Faslodex, Femara, Fenretinide, Gleevec, GTI-2040, Herceptin, Iressa, ISIS-2503, Lapatinib, Nolvadex, Sarasar, SDX-105, Tarceva, Theratope Velcade, Zarnestra, Zoladex ZD0473 and many other that are in an earlier stage of development. Example of companies included: More than 170 companies have been identified within the sphere of breast cancer and the biggest players within this field are listed below: American Bioscience bioscience /bio·sci·ence/ (-si´ens) the study of biology wherein all the applicable sciences (physics, chemistry, etc.) are applied. bi·o·sci·ence n. See life science. , AnorMED, AstraZeneca, Biomira Inc, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were , Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. , Genentech, GlaxoSmithKline, ISIS Pharmaceuticals, Johnson and Johnson, Lorus Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , McNeil Pharmaceuticals, Merck KgaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , Millennium Pharmaceuticals Millennium Pharmaceuticals NASDAQ: MLNM is a biotechnology company based in the Cambridge, Massachusetts area of the United States of America. Founded in 1993, the company conducts research in various scientific areas, currently focusing on inflammation and oncology. , NeoRx, Novartis, OSI Pharmaceuticals OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ , Pfizer, Roche, Salmedix, Schering-Plough and Wyeth The report will assist you in: - Tracking cutting edge companies, therapies and new technologies - Rapid identification of promising drug candidates and future partners & competitors - Fast identification of in-licensing opportunities - Laying down a comprehensive framework for further analysis of the breast targeting field - Producing presentations surrounding the development of cancer therapeutics - Identifying novel breast cancer targeting agents For more information visit http://www.researchandmarkets.com/reports/c23164 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion